Equillium (EQ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Mar, 2026Executive summary
The annual meeting will be held virtually on May 28, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 1, 2026.
Four key proposals are up for vote: election of two Class II directors, approval of a reverse stock split, ratification of Crowe LLP as auditor, and an increase in authorized common shares.
The Board recommends voting in favor of all proposals and provides detailed instructions for participation and voting.
Voting matters and shareholder proposals
Proposal 1: Elect two Class II directors (Charles McDermott and Bruce D. Steel) to serve until 2029.
Proposal 2: Approve a reverse stock split at a ratio between 1-for-2 and 1-for-20, at the Board's discretion, effective by December 31, 2027.
Proposal 3: Ratify Crowe LLP as independent auditor for fiscal year ending December 31, 2026.
Proposal 4: Approve an increase in authorized common shares from 200,000,000 to 400,000,000.
Shareholders may submit proposals for the 2027 annual meeting according to specified deadlines and procedures.
Board of directors and corporate governance
The Board will reduce from seven to six members prior to the meeting; four directors are deemed independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independent membership.
Board diversity, oversight of strategy, and cybersecurity risk management are emphasized.
Regular executive sessions are held with only independent directors present.
Latest events from Equillium
- EQ504 targets UC with a novel, validated approach and is fully funded through key milestones.EQ
Corporate presentation30 Mar 2026 - EQ504 clinical trials set for 2026, $85M raised, cash runway into 2029, no 2025 revenue.EQ
Q4 202525 Mar 2026 - EQ504 advances as a differentiated AhR modulator for UC, with phase I set for mid-year and strong financial backing.EQ
Piper Sandler Virtual Novel Targets in Immunology Symposium12 Feb 2026 - EQ101 shows promise in moderate alopecia areata; key Ono partnership milestone decision imminent.EQ
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Awaiting Ono's decision on itolizumab, while advancing multi-cytokine assets toward the clinic.EQ
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Ono's upcoming decision could trigger a $35M payment and advance pivotal clinical programs.EQ
H.C. Wainwright 26th Annual Global Investment Conference21 Jan 2026 - EQ504, a potent AhR modulator for ulcerative colitis, enters clinical development after major financing.EQ
Cantor Global Healthcare Conference 202531 Dec 2025 - Itolizumab improved long-term outcomes and safety in first-line acute GVHD Phase 3 study.EQ
Study Result26 Dec 2025 - 52.6 million shares registered for resale after $30M private placement; no proceeds to issuer.EQ
Registration Filing16 Dec 2025